Ironwood Pharmaceuticals, Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. The unaudited filing describes Ironwood as a gastrointestinal-focused healthcare company. Its principal commercial product is LINZESS, marketed with AbbVie in the U.S.; international commercialization is supported by AbbVie, Astellas and AstraZeneca.
Financial performance
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Total revenue | $103.7 million | $103.5 million | $296.6 million | $272.8 million |
| Operating income | $65.2 million | $45.6 million | $175.7 million | $91.6 million |
| Net income | $55.8 million | $34.4 million | $487.1 million | $63.0 million |
| Diluted EPS | $0.34 | $0.21 | $2.97 | $0.39 |
| Operating cash flow | Not separately reported | Not separately reported | $197.3 million | $117.3 million |
- Q3 collaborative arrangements revenue was $103.7 million, essentially unchanged year over year. Nine-month collaborative revenue increased 11% to $295.8 million, primarily reflecting a $28.8 million increase in Ironwood’s U.S. LINZESS profit share, attributed to higher prescription demand and inventory fluctuations, partly offset by lower net price.
- Nine-month total revenue rose 9%; API revenue fell $4.7 million as China supply responsibilities transitioned to AstraZeneca. No API revenue was recorded in Q3.
- Operating expenses declined 33% year over year in both the quarter and nine-month period. Nine-month R&D fell 46%, mainly due to discontinued IW-3718 development; SG&A fell 22%, including lower compensation, professional fees and marketing costs.
- Operating margin was approximately 63% in Q3 versus 44% a year earlier, and 59% for the first nine months versus 34%. These are calculated from reported revenue and operating income.
- Nine-month net income included a $335.2 million noncash tax benefit from releasing the valuation allowance on most tax attributes and deferred tax assets. The filing says future tax expense is expected to include substantial noncash expense as deferred tax assets are used. Thus, reported nine-month earnings are not a measure of recurring operating performance alone.
- Cash and cash equivalents were $574.3 million at September 30, 2021, up from $362.6 million at December 31, 2020. Including restricted cash, period-end cash was $576.0 million. Nine-month operating cash flow was $197.3 million; investing cash outflow was $0.1 million and financing cash inflow was $14.0 million.
- Total assets were $1.079 billion and stockholders’ equity was $579.9 million. The balance sheet included $335.2 million of deferred tax assets. Current assets were $695.4 million and current liabilities $145.7 million.
- Convertible notes had $520.7 million aggregate principal outstanding; net carrying value was $448.0 million. Of principal, $120.7 million due in June 2022 was classified as current. Nine-month interest expense was $23.2 million. Operating lease liabilities totaled $22.1 million.
Material developments, outlook and risks
- Management said September 30 cash was expected to fund projected operating needs for at least the next 12 months. No specific revenue or earnings guidance was provided. The company expects continued investment in LINZESS, GI development programs and pipeline opportunities, and cautioned that actual cash needs and results may differ materially from estimates.
- In May 2021, Ironwood and AbbVie settled with Teva, granting a license for a generic 72 mcg LINZESS product beginning March 31, 2029, subject to FDA approval and specified conditions.
- In August 2021, the FDA revised LINZESS labeling based on pediatric safety data. The boxed warning for serious dehydration and the contraindication now apply to children under two; safety and effectiveness under age 18 remain unestablished, and pediatric studies continue.
- In November 2021, after quarter-end, Ironwood entered a COUR Pharmaceuticals option collaboration for CNP-104, a potential primary biliary cholangitis treatment. Terms include a $6.0 million upfront payment, further study and milestone payments, a possible $35.0 million license payment, royalties and up to $440.0 million in commercial milestones.
- A $150.0 million share repurchase authorization was approved in May 2021; no shares had been repurchased by September 30. The company also expects to pay $120.7 million of 2022 notes within 12 months.
- Key risks include heavy dependence on U.S. LINZESS revenue and AbbVie collaboration economics; pricing, reimbursement and competition; patent challenges and generic entry; reliance on partners and third-party manufacturers; regulatory and clinical-development uncertainty; and potential COVID-19 effects on promotion, patient access, trials and supply. The company reported no significant LINZESS supply disruption from COVID-19 as of the filing date.
- Other unusual items include the prior discontinuation of IW-3718 following a Phase III study failure and MD-7246 after a Phase II study missed key endpoints. The Alnylam promotional agreement terminated effective September 30, 2021, though qualifying GIVLAARI royalties may continue through September 2022.
- Management stated disclosure controls were effective and no material change to internal control over financial reporting occurred during the period. The principal financial officer role changed in July 2021.
Important facts for investors to verify
- Whether U.S. LINZESS prescription growth, net pricing and AbbVie cost-sharing continue to support collaborative revenue and cash generation.
- The timing, conditions and patent implications of Teva’s 2029 generic license, and the status of any other generic challenges.
- Cash requirements and refinancing or repayment plans for the $120.7 million 2022 notes, alongside the 2024 and 2026 maturities.
- The assumptions supporting recognition and future utilization of deferred tax assets, including the sustainability of profitability.
- Funding, clinical progress and potential future commitments under the COUR option agreement and other pipeline investments.
- Exposure to partner execution, manufacturing, reimbursement, COVID-19 and regulatory risks, including ongoing pediatric LINZESS studies.